New drug combo aims to slow advanced lung cancer progression
NCT ID NCT03909334
First seen Nov 01, 2025 · Last updated Jun 10, 2026 · Updated 26 times
Summary
This study tests whether adding ramucirumab to the standard drug osimertinib can better control advanced EGFR-mutant lung cancer. About 160 people with non-squamous non-small cell lung cancer that cannot be surgically removed will be randomly assigned to receive either the combination or osimertinib alone. The main goal is to see if the combination delays cancer growth or death longer than the single drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Columbia University Irving Medical Center
New York, New York, 10032, United States
-
Fred Hutchinson Cancer Research Center
Seattle, Washington, 98109, United States
-
Georgetown University
Washington D.C., District of Columbia, 20057, United States
-
Indiana Univesity Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, 46202, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
New York University Cancer Center
New York, New York, 10016, United States
-
Northwestern University Feinberg School of Medicine
Chicago, Illinois, 60611, United States
-
Providence Portland Medical Center
Portland, Oregon, 97213, United States
-
Rush University Medical Center
Chicago, Illinois, 60612, United States
-
Summit Medical Group, PA
Berkeley Heights, New Jersey, 07922, United States
-
University of Virginia Health System
Charlottesville, Virginia, 22908, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.